German specialty-chemicals company making additives, industrial intermediates and consumer-protection chemicals, spun off from Bayer.
German specialty-chemicals company making additives, industrial intermediates and consumer-protection chemicals, spun off from Bayer.
Sells specialty chemicals to industrial customers, with Europe the home base. In 2023 it put its engineering-plastics business into Envalior, a joint venture with the investor Advent in which it kept a minority stake; its 2026 sale attempt fell through, with later windows in 2027 and 2028. It has been shifting toward consumer-related products.
In one line: A German specialty-chemicals peer to Ashland/Albemarle.
Moat: narrow (process know-how, scale). Established specialty-chemical process technology and customer relationships, but commodity-adjacent segments face cyclical pricing.
Headquarters: Cologne, Germany · Founded: 2004 · Employees: 11,709
Size Lanxess (LXS.DE) is a Germany Materials company (Chemicals: Major Diversified) with a market value of $1.19B, the 133rd largest of 198 Germany companies the cockpit tracks. Shares closed at €12.55 on 18 Nov 2026.
Performance Over six months the shares fell 24.4%, against -31.1% for the median peer and -0.9% for the Germany market (cap-weighted) — 10th highest of 21 in its peer set.
Growth Revenue fell 3.6% over the last twelve months (peer median +4.1%); the operating margin is -0.5% (peer median 12.7%).
Valuation It trades at 0.6× enterprise value to sales against a peer median of 2.4× (2nd cheapest of 21).
Price implies For today's price to make sense, revenue must grow about 5% a year for seven years (Req g). Recent delivered growth is -1%, so the hurdle is +7 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
Capital Return on invested capital runs 5.8 points below its cost of capital (5.5% WACC).
Credit Lanxess has 5 bonds outstanding ($2.55B), rated NR by the agencies and trading like BB- at a weighted spread of 260 bp.
Next results Next results expected around 17 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | €5.67B | €5.67B | €6.37B | €6.71B | €8.09B |
| Revenue growth | — | -11% | -5% | -17% | — |
| Gross profit | €1.11B | €1.13B | €1.30B | €1.27B | €1.94B |
| EBITDA | €671M | €497M | €609M | €522M | €989M |
| Net income | -€662M | -€577M | -€177M | €443M | €250M |
| Free cash flow | €118M | -€56.0M | €158M | €464M | -€301M |
| Capital expenditure | €326M | €319M | €320M | €326M | €407M |
| Total debt | €2.98B | €2.53B | €3.01B | €3.01B | €4.25B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g |
|---|---|---|---|---|---|---|
| Lanxess LXS.DE | $1.19B | -24% | -4% | 0% | 0.6× | 5.3% |
| Evonik Industries EVK.DE | $11.1B | +27% | +2% | 10% | 1.0× | -5.6% |
| Clariant CLN.SW | $4.20B | +35% | -7% | 10% | 1.4× | -3.3% |
| Albemarle ALB | $10.1B | -49% | +24% | 17% | 2.1× | 5.6% |
| Ashland ASH | $3.50B | +36% | +2% | 7% | 2.4× | 12.7% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | LXS.DE | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +1.4% | -12.1% | 5th highest of 21 |
| 6-month return | -24.4% | -31.1% | 10th highest of 21 |
| Distance from 52-week high | -43.0% | -48.8% | 10th highest of 21 |
| Revenue growth (TTM) | -3.6% | +4.1% | 6th lowest of 21 |
| Operating margin | -0.5% | 12.7% | 5th lowest of 21 |
| EV / Sales | 0.6× | 2.4× | 2nd cheapest of 21 |
| Growth the price implies (Req g, 7 yrs) | 5.3% | 8.5% | 5th least demanding of 14 |
| Growth delivered (Del g) | -1.5% | +7.4% | lowest of 14 |
| Hurdle (Req g minus delivered) | +6.7 pp | -1.6 pp | 6th most demanding of 14 |
| ROIC minus cost of capital | -5.8 pp | -1.3 pp | 5th lowest of 21 |
| EV / EBITDA | 4.7× | 13.4× | 2nd cheapest of 9 |
| Net debt / EBITDA | 3.0× | 0.5× | most indebted of 9 |
| Bond spread | 260 bp | n/a | — |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Lanxess LXS.DE | Germany | $1.19B | -24% | -4% | 0% | 0.6× | 5.3% | -1.5% |
| Jilin Chemical Fibre Stock 000420.SZ | China | $1.20B | -34% | +11% | 5% | 2.6× | n/a | n/a |
| Hubei Jianghan New Materials 603281.SS | China | $1.15B | -38% | +8% | 17% | 2.4× | 3.9% | +6.3% |
| Jinan Acetate Chemical 4763.TW | Taiwan | $1.14B | -5% | -24% | 43% | 1.9× | -20.2% | +41.2% |
| CNSIG Inner Mongolia Chemical Industry 600328.SS | China | $1.12B | -36% | -20% | -7% | 1.7× | n/a | n/a |
| Shanghai Emperor of Cleaning Hi-Tech 603200.SS | China | $1.12B | -24% | +4% | -8% | 15.2× | n/a | n/a |
| Jiangsu Shuangxing Color Plastic New Materials 002585.SZ | China | $1.27B | -10% | -4% | -4% | 2.0× | 21.0% | +0.2% |
| Nippon Soda 4041.T | Japan | $1.29B | +11% | 0% | 10% | 1.5× | 5.2% | +1.8% |
| China Resources Chemical Innovative Materials 301090.SZ | China | $1.30B | -33% | +4% | 1% | 0.5× | 20.6% | +1.1% |
| Qingdao Huicheng Environmental Technology 300779.SZ | China | $1.08B | -48% | -13% | 5% | 10.4× | n/a | n/a |
| Victrex VCT.L | United Kingdom | $1.06B | +46% | -1% | 14% | 2.8× | 16.7% | +1.9% |
| Metis TechBio 7666.HK | Hong Kong | $1.05B | -64% | +6,987% | -367% | 45.2× | n/a | n/a |
| Rianlon 300596.SZ | China | $1.35B | -15% | +11% | 11% | 1.8× | n/a | n/a |
| Hanchem 014680.KS | South Korea | $1.35B | -49% | +11% | 17% | 2.1× | 5.8% | +7.4% |
| Xinxiang Richful Lube Additive 300910.SZ | China | $1.36B | -33% | +12% | 16% | 2.4× | 2.1% | +32.5% |
| Jubilant Ingrevia JUBLINGREA.NS | India | $1.00B | -19% | +15% | 10% | 2.0× | 28.0% | +44.9% |
| Privi Speciality Chemicals PRIVISCL.NS | India | $1.44B | +11% | +18% | 20% | 5.2× | 30.6% | +15.0% |
| Caregen 214370.KS | South Korea | $982M | -74% | -2% | 20% | 16.8× | 36.8% | +3.8% |
| Dalian Bio-Chem 603360.SS | China | $971M | -54% | 0% | 16% | 5.1× | 8.5% | +18.4% |
| Raghav Productivity Enhancers RPEL.NS | India | $942M | +109% | +38% | 28% | 27.9× | n/a | n/a |
| Jiangsu Zhengdan Chemical Industry 300641.SZ | China | $914M | -29% | -30% | 17% | 2.2× | 7.1% | +11.6% |
Lanxess has 5 bonds outstanding with $2.55B face value. The agencies rate it NR; its bonds trade like BB-. Weighted yield 5.71%, a spread of 260 bp over government bonds.